Skip to main content
Fig. 8 | Stem Cell Research & Therapy

Fig. 8

From: Systemically administered allogeneic mesenchymal stem cells do not aggravate the progression of precancerous lesions: a new biosafety insight

Fig. 8

Low doses of systemically administered allogeneic MSCs preclude OSCC tumor growth. At hyperplasia, dysplasia, or papilloma stage, hamsters received intracardially vehicle or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. At end of study period (13 weeks), tumor volume was assessed. (number of replicates = 2, n = 14). MSC mesenchymal stem cell

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512